A Phase 4 interventional study of Chlorzoxazone and Orphenadrine Citrate in Orofacial Pain and Bruxism, sponsored by University of Baghdad. Recruiting at 1 site in Iraq. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by University of Baghdad · Phase 4, Interventional, and Treatment
To evaluate the clinical effectiveness of chlorzoxazone in comparison to orphenadrine Citrate in relieving the orofacial pain in bruxers. Subjects and Methods: 60 patients above 15-years old complaining of orofacial and temporomandibular disorder/pain, with no history of chronic systemic illness, will be recruited. Patients will randomly be allocated into two groups (n=30): the first group will receive Relaxon (chlorzoxazone) twice daily for two weeks, while the second group will receive Norgesic (orphenadrine Citrate) twice daily for two weeks as well. Pain severity will be assessed by Visual Analogue Scale (VAS) at day 0, 7, and day 14. In addition, a temporomandibular joint (TMJ) evaluation form will be utilized to assess the TMJ parameters before and after initiation of the treatment protocol, i.e at 0 and 14 days. Non parametric statistical analysis will be conducted to explain the results using SPSS V29.
182 studies on the registry are indexed under Facial Pain; 61 are open to participants now.
This study's planned enrollment of 60 is above the median of 50 across 132 interventional studies indexed under Facial Pain.
Browse Facial Pain studies →University of Baghdad is the lead sponsor of 170 studies on the registry; 69 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Using Chlorzoxazone
Drug: Chlorzoxazone
Drug: Orphenadrine Citrate
This group will receive Chlorzoxazone twice daily for two weeks
This group will receive Orphenadrine Citrate twice daily for two weeks.
Change From Baseline in Orofacial Pain Score in Bruxism Patients (n=30) as Measured by the Visual Analog Scale (VAS) in retaliation to adverse effect of each drug used.
Time frame: From enrollment to the end of treatment at 2 weeks
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Chlorzoxazone · Orphenadrine